Showing 5361-5370 of 8820 results for "".
- AMSPA Merges with IALAhttps://practicaldermatology.com/news/amspa-merges-with-iala/2457688/The American Med Spa Association (AmSpa) is merging with the International Aesthetic and Laser Association, Inc. (IALA). The
- Novartis Enters Licensing Deal for IL-17C Compound for Atopic Dermatitishttps://practicaldermatology.com/news/novartis-enters-licensing-deal-for-il-17c-compound-for-atopic-dermatitis/2457689/Novartis has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen (Belgium) and MorphoSys AG, Planegg/Munich (Germany) to acquire the exclusive global development and marketing rights to MOR106 for atopic dermatitis and all other potential indications. Novarti
- Skin Cancer Foundation Accepting Grant Applicationshttps://practicaldermatology.com/news/skin-cancer-foundation-accepting-grant-applications/2457690/The Skin Cancer Foundation is now accepting applications for support of pilot research projects related to skin cancer. Two grants of $50,000 and one grant of $25,000 will be awa
- AD Takes Big Toll on QOLhttps://practicaldermatology.com/news/ad-takes-a-big-toll-on-qol/2457691/Itch, dryness and other eczema symptoms negatively affect quality of life, according to a new study published in the Annals of Allergy, Asthma and Immunology. Of 602 adults with eczema, symptoms that were the bigg
- Sensus Healthcare Forms Strategic Agreement with SkinCure Oncologyhttps://practicaldermatology.com/news/sensus-healthcare-forms-strategic-agreement-with-skincure-oncology/2457697/Sensus Healthcare, Inc., which specializes in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), formed a strategic agreement focused on marketing the SRT-100 Vision with SkinCure Oncology, a leading turnkey provider
- Fourth Generation Retinoid Shows Promise in Acne Trialshttps://practicaldermatology.com/news/fourth-generation-retinoid-shows-promise-in-acne-trials/2457699/New research reveals that trifarotene, a fourth-generation retinoid with potent and selective activity against only one particular retinoic acid receptor, may have an improved efficacy and safety profile compared with less selective r
- About 415 Million People May Have Rosacea Worldwidehttps://practicaldermatology.com/news/about-415-million-people-may-have-rosacea-worldwide/2457701/As many as 415 million people worldwide may have rosacea, according to new research in the British Journal of Dermatology. Dr. Jacob Thyssen and colleagues at the University of Copenhagen, Denmark, conducted
- PAH after Cryolipolysis May Not Be So 'Rare'https://practicaldermatology.com/news/pah-after-cryolipolysis-may-not-be-so-rare/2457707/Paradoxical adipose hyperplasia (PAH) after cryolipolysis may be more common than previously thought according to a paper in the July issue of Plastic and Reconstructive Surgery®. While PAH can be treated successfully
- XELJANZ Receives EU Marketing Authorization for Adults with Active PsAhttps://practicaldermatology.com/news/xeljanz-receives-eu-marketing-authorization-for-adults-with-active-psa/2457706/The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-mod
- FDA Approves Dermira's Qbrexza Cloth to Treat Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/fda-approves-delmiras-qbrexza-cloth-to-treat-primary-axillary-hyperhidrosis/2457709/The FDA has approved Qbrexza™ (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza is applied directly to the skin and is designed to block sweat production by inhib